Endocrinology and Nutrition UGC, Hospital Universitario Virgen de La Victoria, Málaga, Spain.
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Hospital Clínico Virgen de La Victoria, Málaga, Spain.
Curr Obes Rep. 2024 Sep;13(3):403-438. doi: 10.1007/s13679-024-00561-4. Epub 2024 May 4.
The present study aims to review the existing literature to identify pathophysiological proteins in obesity by conducting a systematic review of proteomics studies. Proteomics may reveal the mechanisms of obesity development and clarify the links between obesity and related diseases, improving our comprehension of obesity and its clinical implications.
Most of the molecular events implicated in obesity development remain incomplete. Proteomics stands as a powerful tool for elucidating the intricate interactions among proteins in the context of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature. This systematic review was conducted following the PRISMA guidelines and included sixteen human proteomic studies, each of which delineated proteins exhibiting significant alterations in obesity. A total of 41 proteins were reported to be altered in obesity by at least two or more studies. These proteins were involved in metabolic pathways, oxidative stress responses, inflammatory processes, protein folding, coagulation, as well as structure/cytoskeleton. Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease. Among them, seven proteins, which belong to metabolic pathways (aldehyde dehydrogenase and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3) and oxidative stress and inflammation proteins (catalase and complement C3), could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. Our systematic review in proteomics represents a substantial step forward in unravelling the complexities of protein alterations associated with obesity. It provides valuable insights into the pathophysiological mechanisms underlying obesity, thereby opening avenues for the discovery of potential biomarkers and the development of personalized medicine in obesity.
本研究旨在通过对蛋白质组学研究进行系统综述，来综述肥胖相关的病理生理学蛋白，以明确肥胖相关的蛋白标志物。蛋白质组学可能揭示肥胖发生的机制，并阐明肥胖与相关疾病之间的联系，从而增进我们对肥胖及其临床意义的理解。
大多数与肥胖发生相关的分子事件仍不明确。蛋白质组学是阐明肥胖背景下蛋白质之间复杂相互作用的有力工具。该方法可识别参与病理过程的蛋白，并评估肥胖发生过程中蛋白丰度的变化，有助于发现疾病早期易感性，监测干预措施的有效性，并整体改善疾病管理。尽管有许多非靶向蛋白质组学研究探索肥胖，但缺乏对肥胖相关分子事件的全面、最新的系统综述。对于试图解释现有文献的研究人员来说，这是一个重大的挑战。本系统综述遵循 PRISMA 指南进行，共纳入 16 项人体蛋白质组学研究，每项研究都描述了肥胖中表现出显著改变的蛋白。共有 41 种蛋白在肥胖中至少有两项研究报道发生改变。这些蛋白参与代谢途径、氧化应激反应、炎症过程、蛋白折叠、凝血以及结构/细胞骨架。许多肥胖的蛋白质组学生物标志物也被报道在肥胖相关疾病中失调。其中，属于代谢途径（醛脱氢酶和载脂蛋白 A1）、伴侣家族（白蛋白、热休克蛋白 beta 1、蛋白二硫键异构酶 A3）和氧化应激及炎症蛋白（过氧化氢酶和补体 C3）的 7 种蛋白，可能作为肥胖进展和合并症发生的生物标志物，为肥胖领域的个体化医学提供依据。本综述在蛋白质组学方面代表了在揭示肥胖相关蛋白改变的复杂性方面迈出的重要一步。它为肥胖的病理生理学机制提供了有价值的见解，从而为肥胖相关的潜在生物标志物的发现和个体化医学的发展开辟了道路。
